Novabay Pharmaceuticals Incの簿価
Novabay Pharmaceuticals Incの簿価 は何ですか。
Novabay Pharmaceuticals Incの簿価 は0.49です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
NYSEMKTのセクタHealth Careにおける簿価 の企業と比べるNovabay Pharmaceuticals Inc
Novabay Pharmaceuticals Incは何をしますか。
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Incと類似の簿価
- Townsquare Media Incの簿価 は0.49です。
- Kathmanduの簿価 は0.49です。
- NZMEの簿価 は0.49です。
- X-Terra Resourcesの簿価 は0.49です。
- TAV Havalimanlari ASの簿価 は0.49です。
- 17033の簿価 は0.49です。
- Novabay Pharmaceuticals Incの簿価 は0.49です。
- Laramide Resourcesの簿価 は0.49です。
- Mobotix AGの簿価 は0.49です。
- Fab-Form Industriesの簿価 は0.49です。
- Fireweed Zincの簿価 は0.49です。
- Century Ginwa Retailの簿価 は0.49です。
- Eurasia Fonciere Investissements Societe Anonymeの簿価 は0.49です。